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Cyclosporine G Analysis and Monitoring 
by High-Pressure Liquid Chromatography 
L Zaghloul, G.J. Burckart, T.E. Starzl, S. Todo, R.J. Ptachcinski, and R. Venkataramanan 
CYCLOSPORINE G, or Nva2-cyclospo-
rine (CsG), is a member of a class of 
compounds produced by the fungus Tolypo-
cladium inflatum GAMS that have marked 
immunologic activity. Cyclosporine (CsA) is 
the most extensively studied compound of the 
group and has been very successful in clinical 
use as an immunosuppressant in organ trans-
plantation. The major problem with the clini-
cal use of CsA is its propensity to produce 
nephrotoxicity in patients at a wide range of 
doses. CsG is very similar structurally to CsA 
and has been reported to lack nephrotoxicity 
in a rat model.! 
CsG has been shown to be equally potent as 
CsA in preventing rejection of transplanted 
livers in the canine model. 2 Any comparative 
study of CsA and CsG should also assess 
potential pharmacokinetic differences in the 
two compounds. Previous studies have shown 
that the distribution of cyclosporine in blood is 
highly dependent on the temperature. A 
knowledge of the temperature-dependent dis-
tribution of esG in blood is therefore essential 
for designing a pharmacokinetic study. The 
following study was designed to support a 
comparative study of esA and esG in canine 
liver transplantation. Our objectives were to 
(l) establish an assay for esG; (2) investigate 
the effect of temperature on blood and plasma 
concentrations of esG; and (3) assay canine 
samples over a course of therapy with CsG. 
MATERIALS AND METHODS 
esC Assay 
CsG was assayed using high-pressure liquid chroma-
tography (HPLC). CsA was used in the internal stan-
dard. Blood and plasma samples were extracted by a 
previously described procedure. 3 The final residue was 
dissolved in the mobile phase (200 ,iLl) and injected (ISO 
Ill) onto the HPLC column. 
A 5-/-L, IS-em, CIS column (Supelco, Bellefonte, PAl 
heated to 70°C was used to separate compounds of 
interest. The mobile phase consisted of 68:32 acetoni-
trile:water pumped at a rate of 1.5 mL/min. CsA and 
CsG were quantitiated by their absorbance at 214 nrn 
(Waters Model 441, Milford, MA), Under these condi-
tions, the retention time for CsA and CsG were 7.1 and 
9.7 minutes, respectively. 
Recovery, Reproducibility, and Accuracy 
CsG was spiked into blank blood or plasma in the 
concentrations of 50, 250, 500, J ,000, and 2,000 ng/rnL 
to assess the recovery of the drug using the liquid extrac-
tion. The internal standard (CsA, 250 ng) was added at 
the end of the extraction, and a standard curve of the peak' 
height ratios (CsG/CsA) v CsG concentration was estab-
lished. Percentage of recovery was calculated as the slope 
of the extracted drug standard curve divided by the slope 
of the un extracted drug standard curve (methanolic solu-
tion of CsG) times 100. The accuracy of the assay was 
determined by spiking whole blood with esG (1,240 
ng/tnL) and performing eight repetitions of the drug 
extraction and assay. Assay reproducibility was assessed 
at 250 and 500 ng/mL by assaying six sets of spiked 
whole blood samples. 
Stability 
CsG stability in whole blood was determined at room 
temperature and at 46°C for a period of ten days. 
Blood-Plasma Ratio 
The effect of temperature on the blood-plasma ratio of 
CsG was determined at 5, 25, and 37 0c. Fresh heparin-
ized blood was spiked with 1,240 ng/mL CsG and was 
maintained at the appropriate temperature for two hours. 
The blood was then spun in a thermostatically controlled 
centrifuge to obtain the plasma, which was assayed along 
with the whole blood. 
Canine Studies 
female beagle and mongrel dogs underwent orthotopic 
liver transplantation and were randomly selected to 
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receive either CsA or CsG. The dogs received either drug 
in an oral olive oil solution in the dose of 20 mg/kg for the 
first 30 days following transplantation, after which the 
dose was reduced to 15 mg/kg body weight. Blood was 
obtained every third day in the morning for HPLC 
analysis of CsG or CsA. 
RESULTS 
Extracts of blank blood and plasma indi-
cated the lack of interference of any endoge-
nous materials with CsG or CsA. The mini-
mum detectable concentration of CsG was 25 
ng/mL using 1 mL of blood or plasma. The 
HPLC assay for CsG was linear over 50 to 
2,000 ng/mL as demonstrated by consistent 
correlation coefficients of greater than 0.998. 
The liquid-liquid extraction procedure used in 
the present assay yielded recovery values of 
90% for CsG in both blood and plasma. In the 
accuracy study, the whole blood was spiked 
with 1,240 ng/mL of CsG and was assayed as 
having 1,156 ng/mL on eight repetitions, rep-
resenting a percentage of error of 6.8%. The 
coefficient of variation of this assay was 4.0% 
at 250 ng/mL and 2.5% at 500 ng/mL for 
CsG in whole blood. Assays performed on 
spiked whole blood maintained at room tem-
perature or at 46 °C for up to ten days indi-
cated no loss of CsG from the samples. 
The distribution of CsG in blood is temper-
ature dependent. The blood-plasma ratio (B/ 
P) is 1.45, 1.2, and 0.9 at SoC, 26 °C, and 37 
°C, respectively. 
The trough concentrations of CsG in an 
individual dog over the course of therapy are 
shown in Fig 1. The dose reduction on day 30 
did not result in a marked decrease in trough 
CsG concentrations. The morning predose 
whole blood CsG concentrations generally 
increased over the first 20 to 30 days of 
therapy. The concentration of CsG was signif-
icantly higher than CsA concentrations at 
days 36, 57, 63, 66, 69, 81, 84, and 87 of 
therapy (P < 0.05 by t test). The average 
trough concentration of CsG (409 ng/mL) 
was higher than that of esA (236 ng/mL). 
The dogs in both groups had a significantly 
longer survival time (P < 0.05) when their 
trough blood concentration was greater than 
200 ng/mL. 
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Fig 1. CsG blood concentration v time in a dog who 
was given 20 mg/kg/day CsG on days 0 to 30 and 15 
mg/kgl day on days 30 to 90 following orthotopic liver 
transplantation. 
DISCUSSION 
CsG is a promising immunosuppressant for 
use in organ transplantation. CsG has been 
shown to be as effective as CsA in preventing 
organ rejection in rodent transplant models l 
and in the canine studies for which the HPLC 
CsG assay was developed.2 Nephrotoxicity 
has not appeared in toxicologic rat studies 
with CsG l and was not a problem in the 
canine study even though CsG blood concen-
trations were frequently high. Decreased 
nephrotoxicity would provide CsG with a sig-
nificant advantage over CsA while other bio-
pharmaceutical problems, such as intersub-
ject variability in pharmacokinetics, would 
most likely remain. 
The HPLC assay described for CsG dem-
onstrates the flexibility of HPLC for monitor-
ing immunosuppressive compounds of cyclo-
sporine family. Only minor modifications of 
the HPLC assay of CsA are necessary to 
provide accurate and reproducible blood con-
centration of CsG. A number of compounds of 
the cyclosporine family were tried as internal 
standards; optimal resolution was obtained 
with CsA as the internal standard. 
Preliminary studies with solid phase extrac-
tion techniques yielded poor and variable 
recovery of CsG from blood. The liquid-liquid 
extraction procedure used in this assay consis-
tently provided 90% recovery of esG from 
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whole blood and plasma. Plasma esG can be 
extracted using solid-phase extraction proce-
dures. However, less than 70% of the drug is 
extracted by this method. 
Similar to what has been observed with 
esA, the B /P of CsG is a function of tempera-
ture. As the temperature increases, less and 
less cyclosporine partitions into erythrocytes. 
In theory, this may be due to increased uptake 
of CsG by proteins in the plasma or decreased 
uptake by erythrocytes at higher tempera-
tures. Preliminary evidence suggests that 
erythrocyte uptake is independent of tempera-
ture. Irrespective of the mechanisim involved, 
plasma samples should be separated at 37°C 
in order to obtain meaningful pharmacoki-
netic parameters for CsG. 
Following oral administration, a wide range 
of trough concentrations of CsG were 
observed in dogs even though a consistant dose 
per kilogram of body weight was being admin-
istered. While this variability was predicted 
from observations with CsA, the higher blood 
concentrations of CsG than CsA were unex-
pected. While increased absorption could 
account for higher CsG blood concentrations, 
its poor water solubility (similar to CsA) 
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makes improved absorption of esG over CsA 
unlikely. Altered distribution of CsG, due to 
variable binding to red cells or to plasma 
lipoproteins, or differences in hepatic drug 
clearance, are equally likely to have produced 
higher CsG than CsA blood concentrations. 
SUMMARY 
HPLC provides an accurate and reproduc-
ible means of measuring CsG in blood or 
plasma using CsA as an internal standard. 
The blood-plasma ratio for CsG varies with 
temperature of separation so that whole blood 
monitoring is preferred. CsG blood concentra-
tions were higher than CsA blood concentra-
tions when equal doses of both drugs were 
administered to dogs over a 90-day period. 
Pharmacokinetic differences are therefore 
predicted between esA and CsG. 
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